L
Lodo Therapeutics
Biotech & Life Sciences · New York City, United States · Founded 2015
Drug discovery and development company MoreLess
Lodo Therapeutics is a pioneering company in the field of biofacturing, leveraging advanced biological engineering to develop innovative materials for various industries. The company operates in the high-tech sector, focusing on creating new products by partnering with nature and utilizing cutting-edge bioengineering techniques. Lodo Therapeutics serves clients in the electronics, consumer care, and agriculture markets, providing them with advanced materials that meet the latest and future requirements. The business model revolves around research and development, where the company invests heavily in scientific innovation to create unique, high-value products. Revenue is generated through the commercialization of these advanced materials, which are sold to industry leaders looking for next-generation solutions. The company stands out for its ability to rethink biology and reimagine the world, making significant strides in material science and biofacturing. Keywords: biofacturing, advanced materials, electronics, consumer care, agriculture, bioengineering, innovation, high-tech, research and development, commercialization.
Company overview
Lodo Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2015
- Headquarters
- New York City, United States
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 80.6
- Investment activity
- 1 companies · latest Sep 2020
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Lodo Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | May 2021 | $0 | — | Zymergen | — |
| SERIES A✓Equity / VC | Jan 2016 | $17M | $68M | Pfizer Ventures | — |
| SPINOUT✓Other financing | Sep 2015 | $0 | — | Rockefeller University | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 8 |
| 2025 | 6 |
| 2024 | 6 |
| 2023 | 6 |
| 2022 | 6 |
| 2021 | 7 |
| 2020 | 33 |
Growth signals
Lodo Therapeutics website traffic
Latest recorded traffic for Lodo Therapeutics is 240 monthly website visits, down 42.9% over the last three months. Lodo Therapeutics's team grew 33.3% over the past year.
Comparisons
Lodo Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Lodo Therapeutics investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Lodo Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Lodo Therapeutics has talent and traffic
team presence
In the news
Latest news about Lodo Therapeutics
Recent press, funding announcements, and product moves mentioning Lodo Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about Lodo Therapeutics
An AI-synthesized read of the highest-engagement posts about Lodo Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lodo Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.